tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

MaxCyte Inc

MXCT
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
1.040USD
-0.050-4.59%
์ข…๊ฐ€ย 05/15, 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
111.41M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
๎™

์ž์„ธํ•œ ๋‚ด์šฉ์€ MaxCyte Inc ํšŒ์‚ฌ

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.

MaxCyte Inc ์ •๋ณด

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ MXCT
ํšŒ์‚ฌ ์ด๋ฆ„MaxCyte Inc
์ƒ์žฅ์ผMar 29, 2016
CEOMasoud (Maher)
์ง์› ์ˆ˜114
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒMar 29
์ฃผ์†Œ9713 Key West Avenue,
๋„์‹œROCKVILLE
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€United States of America
์šฐํŽธ ๋ฒˆํ˜ธ20850
์ „ํ™”13015175556
์›น์‚ฌ์ดํŠธhttps://www.maxcyte.com/
์ข…๋ชฉ ์ฝ”๋“œ MXCT
์ƒ์žฅ์ผMar 29, 2016
CEOMasoud (Maher)

MaxCyte Inc์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
398.33K
--
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
230.58K
--
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
-171.43%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
--
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
82.92K
+51.93%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
--
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Non-Executive Independent Director
Non-Executive Independent Director
39.89K
--
Mr. William W. (Will) Brooke, J.D.
Mr. William W. (Will) Brooke, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Patrick J. Balthrop
Mr. Patrick J. Balthrop
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Sandoval
Mr. David Sandoval
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
๋” ๋ณด๊ธฐ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
398.33K
--
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
230.58K
--
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
-171.43%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
--
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
82.92K
+51.93%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
--

์ˆ˜์ต ๋ถ„์„

ํ†ตํ™”: USD๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Apr 6
ํ†ตํ™”: USD๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
์‚ฌ์—…๋ณ„USD
์ด๋ฆ„
์ˆ˜์ต
๋น„์œจ
Product sales
18.69M
56.59%
Product
18.69M
56.59%
Licenses
12.37M
37.45%
other
1.97M
5.95%
์ง€์—ญ๋ณ„USD
์ด๋ฆ„
์ˆ˜์ต
๋น„์œจ
Inside the United States
21.08M
63.82%
Outside the United States
11.95M
36.18%
์‚ฌ์—…๋ณ„
์ง€์—ญ๋ณ„
์‚ฌ์—…๋ณ„USD
์ด๋ฆ„
์ˆ˜์ต
๋น„์œจ
Product sales
18.69M
56.59%
Product
18.69M
56.59%
Licenses
12.37M
37.45%
other
1.97M
5.95%

์ฃผ์‹ ๋ณด์œ  ํ†ต๊ณ„

๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sun, May 10
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sun, May 10
์ฃผ์ฃผ
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Capricorn Fund Managers Ltd
7.65%
BlackRock Institutional Trust Company, N.A.
6.96%
River Global Investors LLP
5.13%
Vitruvian Partners LLP
4.71%
Vanguard Capital Management, LLC
3.72%
๊ธฐํƒ€
71.83%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Capricorn Fund Managers Ltd
7.65%
BlackRock Institutional Trust Company, N.A.
6.96%
River Global Investors LLP
5.13%
Vitruvian Partners LLP
4.71%
Vanguard Capital Management, LLC
3.72%
๊ธฐํƒ€
71.83%
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
๋น„์œจ
Investment Advisor
28.60%
Investment Advisor/Hedge Fund
20.75%
Hedge Fund
8.15%
Private Equity
4.71%
Research Firm
3.93%
Individual Investor
1.37%
Venture Capital
0.32%
Pension Fund
0.21%
Bank and Trust
0.20%
๊ธฐํƒ€
31.76%

๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ 

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Apr 1
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Apr 1
๋ณด๊ณ  ๊ธฐ๊ฐ„
๊ธฐ๊ด€ ์ˆ˜
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
2026Q1
292
79.92M
74.61%
-18.93M
2025Q4
282
79.65M
74.66%
-13.91M
2025Q3
287
82.96M
77.85%
-17.02M
2025Q2
296
78.80M
73.92%
-18.62M
2025Q1
308
82.56M
77.59%
-14.89M
2024Q4
308
80.42M
75.91%
-14.30M
2024Q3
300
80.65M
76.72%
-18.62M
2024Q2
297
80.25M
76.66%
-17.97M
2024Q1
302
79.09M
75.86%
-22.52M
2023Q4
303
79.97M
77.01%
-14.24M
๋” ๋ณด๊ธฐ

์ฃผ์ฃผ ํ™œ๋™

๎™Œ
์ด๋ฆ„
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
Chg %
๋‚ ์งœ
Capricorn Fund Managers Ltd
8.20M
7.67%
+8.20M
--
Jan 30, 2026
BlackRock Institutional Trust Company, N.A.
7.45M
6.98%
-585.24K
-7.28%
Dec 31, 2025
River Global Investors LLP
5.50M
5.14%
+2.24M
+68.99%
Oct 23, 2025
Vitruvian Partners LLP
5.04M
4.72%
--
--
Dec 31, 2025
Cadian Capital Management LP
3.68M
3.45%
-4.54M
-55.24%
Dec 31, 2025
Mudita Advisors LLP
3.37M
3.15%
--
--
Dec 31, 2025
Morgan Stanley & Co. LLC
3.03M
2.84%
-1.22M
-28.66%
Dec 31, 2025
AXA Investment Managers UK Ltd.
2.77M
2.6%
--
--
Dec 31, 2025
Geode Capital Management, L.L.C.
2.52M
2.36%
-41.34K
-1.62%
Dec 31, 2025
๋” ๋ณด๊ธฐ

๊ด€๋ จ ETF

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
์ด๋ฆ„
๋น„์œจ
Invesco NASDAQ Future Gen 200 ETF
0.6%
iShares Micro-Cap ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Russell 2000 Value ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Biotechnology ETF
0.01%
๋” ๋ณด๊ธฐ
Invesco NASDAQ Future Gen 200 ETF
๋น„์œจ0.6%
iShares Micro-Cap ETF
๋น„์œจ0.03%
Invesco Nasdaq Biotechnology ETF
๋น„์œจ0.02%
Avantis US Small Cap Equity ETF
๋น„์œจ0.02%
ProShares Ultra Nasdaq Biotechnology
๋น„์œจ0.02%
iShares Russell 2000 Value ETF
๋น„์œจ0.01%
Proshares Ultra Russell 2000
๋น„์œจ0.01%
iShares Russell 2000 ETF
๋น„์œจ0.01%
Global X Russell 2000 ETF
๋น„์œจ0.01%
iShares Biotechnology ETF
๋น„์œจ0.01%

์ฃผ์‹ ๋ฐฐ๋‹น๊ธˆ

๎™Œ
์ง€๋‚œ 5๋…„ ๋™์•ˆ ์ด 0.00 USD์˜ ๋ฐฐ๋‹น๊ธˆ์ด ๋ถ„๋ฐฐ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.
๋‚ ์งœ
๋ฐฐ๋‹น๊ธˆ
๊ธฐ์ค€์ผ
์ง€๊ธ‰์ผ
๋ฐฐ๋‹น๋ฝ์ผ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ถ„ํ• 

๎™Œ
๋‚ ์งœ
๋ฐฐ๋‹น๋ฝ์ผ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ
๋‚ ์งœ
๋ฐฐ๋‹น๋ฝ์ผ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ
KeyAI
๎™